Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

BACKGROUND: Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity, leading to durable objective responses in a subset of patients across multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yiwen, Carpenito, Carmine, Wang, George, Surguladze, David, Forest, Amelie, Malabunga, Maria, Murphy, Mary, Zhang, Yiwei, Sonyi, Andreas, Chin, Darin, Burtrum, Douglas, Inigo, Ivan, Pennello, Anthony, Shen, Leyi, Malherbe, Laurent, Chen, Xinlei, Hall, Gerald, Haidar, Jaafar N., Ludwig, Dale L., Novosiadly, Ruslan D., Kalos, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925824/
https://www.ncbi.nlm.nih.gov/pubmed/29712568
http://dx.doi.org/10.1186/s40425-018-0329-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925824/
https://www.ncbi.nlm.nih.gov/pubmed/29712568
http://dx.doi.org/10.1186/s40425-018-0329-7

Ejemplares similares